Pliant cuts workforce by 45% following lung trial termination
Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the…
Respiratory
-
-
AstraZeneca’s triple-combo triumphs in two Phase III asthma trials
AstraZeneca’s triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) has met the primary endpoints in two Phase III asthma trials. Breztri met…
-
Rein Therapeutics to integrate Qureight’s platform in trial of IPF treatment
Rein Therapeutics has announced a partnership to integrate UK-based core imaging laboratory Qureight’s deep-learning platform into the upcoming Phase II trial…
-
Amgen’s Phase III trial of Imdelltra meets primary endpoint for SCLC
Amgen's global Phase III DeLLphi-304 trial of Imdelltra (tarlatamab-dlle) has met its primary endpoint at a planned interim analysis for…
-
Qureight and Remedy Cell to validate RC-0315 in Phase Ib trial for IPF
Qureight and Remedy Cell have collaborated to validate the mechanism of action of RC-0315 in the Phase Ib clinical trial…
-
Trevi Therapeutics enrols all subjects in trial of Haduvio for chronic cough in IPF
US-based biopharmaceutical company Trevi Therapeutics has finished enrolling subjects in a Phase IIb trial of investigational Haduvio for treating chronic…
-
Boehringer and partners commence gene therapy trial for cystic fibrosis
Boehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced the Phase I/II…
-
BMS’ Opdivo plus chemotherapy shows OS benefit in Phase III NSCLC study
Bristol Myers Squibb (BMS) has reported outcomes from the Phase III CheckMate -816 trial, indicating an overall survival (OS) benefit…
-
Genprex doses first subject in expansion part of lung cancer gene therapy trial
Genprex has dosed the first subject in the Phase II expansion portion of its Acclaim-3 trial of the Reqorsa gene…
-
FDA grants ODD status to Zai Lab’s lung cancer treatment
The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Zai Lab’s delta-like ligand 3 (DLL3)…
